---
title: "Atossa Therapeutics gets 180 more days to meet Nasdaq $1.00 bid price rule"
url: "https://aibio.space/news/atossa-therapeutics-gets-180-more-days-meet-nasdaq-1-00-bid-price-rule/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-08-21"
section: "Listings"
tickers: "NASDAQ:ATOS"
source: "https://www.sec.gov/Archives/edgar/data/1488039/000095017025110654/atos-20250821.htm"
summary: "The new deadline is February 17, 2026. Atossa said it may consider a reverse stock split if needed."
---

By the aibio.space news desk.

Sources

- [Atossa Therapeutics, Inc. 8-K (2025-08-21)](https://www.sec.gov/Archives/edgar/data/1488039/000095017025110654/atos-20250821.htm)

[ATOS](https://aibio.space/companies/atossa-therapeutics/)

2025-08-21

# Atossa Therapeutics gets 180 more days to meet Nasdaq $1.00 bid price rule

Tickers [ATOS](https://aibio.space/companies/atossa-therapeutics/)

The new deadline is February 17, 2026. Atossa said it may consider a reverse stock split if needed.

## Key facts

- **Company**: Atossa Therapeutics, Inc. (NASDAQ: ATOS)

- **News type**: Listings

- **Primary source**: [Atossa Therapeutics, Inc. 8-K (2025-08-21)](https://www.sec.gov/Archives/edgar/data/1488039/000095017025110654/atos-20250821.htm)

*A columned courthouse. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Atossa Therapeutics, Inc. said on August 21, 2025, that Nasdaq extended its deadline to regain compliance with the minimum bid price rule by 180 days, to February 17, 2026.

The issue goes back to February 21, 2025. That day, The Nasdaq Stock Market LLC told Atossa it did not meet Listing Rule 5550(a)(2) because its common stock had failed to keep a minimum closing bid price of $1.00 per share for 30 consecutive business days. This is known as a bid-price deficiency. A company in that position has a set period to lift its share price back above the threshold or risk delisting.

Atossa's initial compliance period ended on August 20, 2025. The company then requested an extension. It was informed of the new deadline on August 21, 2025.

The notice has no immediate effect on the listing or trading of the company's common stock on Nasdaq. Atossa said it intends to actively monitor the bid price. It said it is committed to considering available options, "including, if necessary, potentially effectuating a reverse stock split." A reverse split combines existing shares into fewer shares, which raises the price of each one.

The report is available as a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1488039/000095017025110654/atos-20250821.htm).

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

ATOS

Atossa Therapeutics, Inc.

NASDAQ · United States

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/atossa-therapeutics-gets-180-more-days-meet-nasdaq-1-00-bid-price-rule/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Atossa Therapeutics gets 180 more days to meet Nasdaq $1.00 bid price rule", 2025-08-21, https://aibio.space/news/atossa-therapeutics-gets-180-more-days-meet-nasdaq-1-00-bid-price-rule/